Eton Pharmaceuticals, Inc. (ETON) Q2 2025 Earnings Call Transcript

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET

Company Participants

David C. Krempa – Chief Business Officer
James R. Gruber – CFO, Treasurer & Secretary
Sean E. Brynjelsen – President, CEO & Director

Conference Call Participants

Chase Richard Knickerbocker – Craig-Hallum Capital Group LLC, Research Division
Madison Britt Wynne El-Saadi – B. Riley Securities, Inc., Research Division
Swayampakula Ramakanth – H.C. Wainwright & Co, LLC, Research Division

Operator

Thank you for standing by. My name is Alex, and I will be your conference operator for today. At this time, I would like to welcome everyone to the Eton Pharmaceuticals Q2 2025 Earnings Call. [Operator Instructions] Thank you.

I would now like to turn the call over to Mr. David Krempa. Please go ahead.

David C. Krempa

Thank you, operator. Good afternoon, everyone, and welcome to Eton’s Second Quarter 2025 Conference Call. This afternoon, we issued a press release that outlines the topics we plan to discuss on today’s call. The release is available on our website, etonpharma.com.

Joining me on our call today, we have Sean Brynjelsen, our CEO; James Gruber, our CFO; and Ipek Trinkaus, our Chief Commercial Officer. In addition to taking live questions on the call today, we will be answering questions that are e-mailed to us. Investors can send their questions to investorrelations@etonpharma.com.

Before we begin, I would like to remind everyone that remarks made during today’s call may contain forward-looking statements and involves risks and uncertainties that could cause actual results to differ materially from those contained in these forward-looking statements. Please see the forward-looking statements disclaimer in our earnings release and the risk factors in the company’s filings with the SEC.

Now, I will turn the call over to our CEO, Sean Brynjelsen.

Sean E. Brynjelsen

Thank